A Phase III, Randomized, Open Label Trial of Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma

What is the purpose of this trial?

The purpose of this study is to test the effectiveness and tolerability of the combination of Nivolumab and Ipilimumab compared to Pemetrexed and Cisplatin or Carboplatin in patients with unresectable pleural mesothelioma.


Participation Guidelines

Ages: 18 years and older

Gender: Both


Bristol-Myers Squibb Company

Dates: 05/22/2017 - 09/15/2020

Last Updated: 05/23/2017

Study HIC#: 1607018103

Get Involved

For more information about this study, contact:
Kira Fitzsimons Pavlik
+1 203-737-2587
kira.pavlik@yale.edu

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 1-877-978-8348.

Trial Image